ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has a beta value of 1.8 and has seen 1,086,843 shares traded in the last trading session. The company, currently valued at $8.04 Billion, closed the last trade at $51.61 per share which meant it gained $1.3 on the day or 2.62% during that session. The ACAD stock price is -4.15% off its 52-week high price of $53.75 and 58.23% above the 52-week low of $21.56. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.73 Million shares traded. The 3-month trading volume is 1.52 Million shares.
The consensus among analysts is that ACADIA Pharmaceuticals Inc. (ACAD) is a Buy stock at the moment, with a recommendation rating of 1.7. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 2 out of 16 have rated it as a Hold, with 14 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.44.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) trade information
Sporting 2.62% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Thursday, Jul 02 when the ACAD stock price touched $52.28- or saw a rise of 1.28%. Year-to-date, ACADIA Pharmaceuticals Inc. shares have moved 20.64%, while the 5-day performance has seen it change 2.83%. Over the past 30 days, the shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have changed 7.48%. Short interest in the company has seen 11.49 Million shares shorted with days to cover at 7.56.
Wall Street analysts have a consensus price target for the stock at $59, which means that the shares’ value could jump 14.32% from current levels. The projected low price target is $41 while the price target rests at a high of $74. In that case, then, we find that the current price level is +43.38% off the targeted high while a plunge would see the stock lose -20.56% from current levels.
ACADIA Pharmaceuticals Inc. (ACAD) estimates and forecasts
Figures show that ACADIA Pharmaceuticals Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained +25.54% over the past 6 months, with this year growth rate of 19.38%, compared to 9.5% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are -15.8% and -48.3% for the next quarter. Revenue growth from the last financial year stood is estimated to be +29.1%.
15 analysts offering their estimates for the company have set an average revenue estimate of $103.71 Million for the current quarter. 15 have an estimated revenue figure of $117.32 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $83.2 Million and $94.59 Million respectively for this quarter and the next, and analysts expect sales will grow by 24.6% for the current quarter and 24% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -10.9% over the past 5 years. Earnings growth for 2020 is a modest +17.5% while over the next 5 years, the company’s earnings are expected to increase by 25%.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s Major holders
Insiders own 0.1% of the company shares, while shares held by institutions stand at 97.57% with a share float percentage of 97.67%. Investors are also buoyed by the number of investors in a company, with ACADIA Pharmaceuticals Inc. having a total of 372 institutions that hold shares in the company. The top two institutional holders are Baker Brothers Advisors, LLC with over 41.9 Million shares worth more than $1.77 Billion. As of March 30, 2020, Baker Brothers Advisors, LLC held 26.89% of shares outstanding.
The other major institutional holder is FMR, LLC, with the holding of over 20.29 Million shares as of March 30, 2020. The firm’s total holdings are worth over $857.29 Million and represent 13.02% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Fidelity Growth Company Fund and Price (T.Rowe) New Horizons Fund. As of March 30, 2020, the former fund manager holds about 4.94% shares in the company for having 7692273 shares of worth $325Million while later fund manager owns 4.29 Million shares of worth $183.6 Million as of December 30, 2019, which makes it owner of about 2.75% of company’s outstanding stock.